Table 4.
Prevalence of Pfcrt polymorphisms in paired pre-treatment and post-treatment samples in the artesunate-amodiaquine treatment arm, therapeutic efficacy monitoring, Mali, 2015 – 2016
| Pre-treatment n, (%)* n = 26 |
Post-treatment n, (%) n = 30 |
p-value** | |
|---|---|---|---|
| Pfcrt point mutations | |||
| Pfcrt codon 72 | |||
| C72 | 26 (100.0) | 30 (100.0) | NA |
| Pfcrt codon 73 | |||
| V73 | 26 (100.0) | 30 (100.0) | NA |
| Pfcrt codon 74 | |||
| M74 | 4 (15.4) | 16 (53.3) | 0.018 |
| 74M/I | 7 (26.9) | 2 (6.7) | |
| 74I | 15 (57.7) | 12 (40.0) | |
| Pfcrt codon 75 | |||
| N75 | 4 (15.4) | 16 (53.3) | 0.018 |
| 75N/E | 7 (26.9) | 2 (6.7) | |
| 75E | 15 (57.7) | 12 (40.0) | |
| Pfcrt codon 76 | |||
| K76 | 4 (15.4) | 16 (53.3) | 0.018 |
| 76K/T | 7 (26.9) | 2 (6.7) | |
| 76T | 15 (57.7) | 12 (40.0) | |
| Pfcrt haplotypes† | |||
| CVIET | 22 (84.6) | 14 (46.7) | 0.082 |
| CVMNK | 11 (42.3) | 18 (60.0) | |
Bold letter denotes an encoded amino acid change
†Haplotype totals include mixed infections
*4 recrudescent infections not included
** Comparing wild-type vs. mutant (excluding mixed infections) for point mutations and CVIET versus CVMNK haplotypes